InsiderTrades

Form 4 for NBIX NEUROCRINE BIOSCIENCES INC

Accepted 2025-02-04 00:00:00 ET · period of report 2025-01-31 · accession 0000914475-25-000032 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-02-04 2025-01-31 NBIX Cooke Julie CHRO M - OptEx $0.00 +1,740 19.9K +10% $0
DM 2025-02-04 2025-01-31 NBIX Cooke Julie CHRO S - Sale+OE $152.89 -1,740 18.2K -9% -$266.0K
D 2025-02-04 2025-01-31 NBIX Cooke Julie CHRO M - OptEx $0.00 -1,740 1,741 -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-01-31 M A 1,740 $0.00 19,942 D — —
2 Common Common Stock 2025-01-31 S D 916 $152.89 19,026 D — — (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.85 to $153.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
3 Common Common Stock 2025-01-31 S D 824 $152.89 18,202 D — — (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.85 to $153.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F4) 16,538 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power
4 Derivative Restricted Stock Unit 2025-01-31 M D 1,740 $0.00 1,741 D — · — to — 1,740 Common Stock (F5) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. (F6) This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 1,740 shares on January 31, 2023, vested as to 1,740 shares on January 31, 2024, vested as to 1,740 shares on January 31, 2025, and will vest as to 1,741 shares on January 31, 2026, subject to the terms and conditions of the award.